Considering the data shown in this work, and upon confirmation of a role for SPRYD7 in angiogenesis induction, SPRYD7 might become an interesting target of intervention in blocking the angiogenic capacity of cancer cells, which might reduce their tumor growth and metastatic potential, with the aim of improving the prognosis and survival of CRC patients, as previously suggested for therapies based on antiangiogenic factors [62,63,64]. This evidence concerns the gene SPRYD7 and neoplasm.